https://www.selleckchem.com/products/prt543.html
27] and 0.86 (95% ci 0.56 to 1.34) respectively. Similarly, no significant improvement in rfs was observed for capecitabine compared with gemcitabine or gemox. Conclusions Although in the present analysis, we found no statistically significant improvements in os or rfs for capecitabine compared with gemox or gemcitabine, capecitabine can-until further prospective trials are completed-be considered the standard of care in the adjuvant setting based on a single randomized phase iii study. 2020 Multimed Inc.Background Lung cancer (lc) is a
Me gusta
Comentario
Compartir
